You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The test, TruGraf, assesses differentially expressed genes in blood to rule out subclinical kidney transplant rejection in patients with stable renal function.
A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.
When used together, ThyGeNext and ThyraMir combine next-generation sequencing of an individual's DNA and RNA along with a microRNA classifier.
The health technology firm is proposing a new software solution that would standardize coding in genetic testing, but a more predictable system would also narrow variability in test pricing.
In response to CMS reopening its national coverage determination to address its germline testing policy, stakeholders point out areas of concern and confusion.
A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractor Palmetto for the week of 8/22/2019.
The Medicare contractor has proposed to cover the non-invasive test for certain kidney and heart transplant patients.
As NGS testing becomes more widespread, labs, payors, and professional groups confront questions about which genes should be required as part of clinical assays.
The firm said that UHC will cover the test for patients with major depressive disorder or anxiety who have failed to respond to one or more treatments.
For the three months ended June 30, the genomic testing firm reported total revenues of $30.1 million.
The company decided to settle the complaint in order to avoid "lengthy and distracting litigation," but denies any wrongdoing.
Stakeholders discussed last year's decision by Palmetto to deny coverage for large respiratory panels and discussed the way forward for test developers and labs.
The organizations provided a list of genes they believe are informative in treatment of myeloid disorders and suggested several changes to the coverage policy.
Interpace Diagnostics' ThyGeNext and ThyraMir thyroid cancer assays are now covered for about 2.5 million patients in Philadelphia and Southeastern Pennsylvania.
Two senators have asked a government watchdog to see if CMS made payments to US providers who have partnered with firms including WuXi NextCode and BGI.
A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors for Noridian for the week of 5/24/19.
The diagnostic will now be a contracted service with Anthem Blue Cross of California and 10 of its affiliated health plans.
The government payor asked the public to specifically weigh in on the evidence supporting germline testing to assess treatment benefit for patients with hereditary cancer syndromes.
A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors for Guardant Health, Natera, Transplant Genomics, and More for the week of 4/26/19.
A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors for Prospera, Noridian, CGS, and more for the week of 4/12/2019.
New analyses indicate female researchers are publishing less during the coronavirus pandemic than male researchers, according to Nature News.
A study suggests people with the ApoE e4 genotype may be more likely to have severe COVID-19 than those with other genotypes, the Guardian says.
Direct-to-consumer genetic testing companies are searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.
In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.